DOCS
Doximity, Inc.
$33.35
+6.04% 2026-10-20
Health CareS&P 400
DOCSSPY
1W
+9.2%
1M
+27.7%
3M
+58.0%
6M
+38.1%
YTD
-24.7%
1Y
-51.0%
Live chart
Loading live chart…
Grades vs sector
Momentum2nd pct in sectorF
Momentum
2nd pct in sector
12-1 return: -57.1%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth43rd pct in sectorC
Growth
43rd pct in sector
Revenue growth (YoY): +7.3%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value32nd pct in sectorD+
Value
32nd pct in sector
Forward E/P: 5.0% · EBITDA/EV: 4.3%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability78th pct in sectorB+
Profitability
78th pct in sector
Profit margin: +25.5% · Return on equity: +17.2%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsKey stats
Market cap$5.9B
P/E (trailing)39.2
P/E (forward)21.4
52-week range17.15 – 71.37
Revenue growth (YoY, latest qtr)+7.3%
Dividend yield0.00%
Analyst consensusHold (18)
Mean price target$31.11 (-7%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
Leans expensive
Model read-out from the numbers below, not advice. Score -2 (DCF counts double).
•DCF (base case)above the price by 14%
▼Forward P/E vs sector21.4x vs median 17.6x
•Piotroski F-score6/9
▲Altman Z23.1 (safe)
▲Net debt / EBITDA-1.3x
▼Analyst target-7% (18 analysts)
Discounted cash flow
Bear
$25
-24%
growth 6% · disc. 11.3% · term. 2.0%
Base
$38
+14%
growth 11% · disc. 10.3% · term. 2.5%
Bull
$54
+63%
growth 14% · disc. 9.3% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 7% a year for 10 years.
Implied
+7%/yr
FCF, last 3 yrs
+22%/yr
FCF, last 5 yrs
+32%/yr
Revenue, last 3 yrs
+15%/yr
Revenue, last 5 yrs
+26%/yr
Same inputs as the DCF above: trailing free cash flow 0.3B, 10.3% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2026; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.22 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
pricier
sector median 29.9× · 70th pct
39.2×pricier
Forward P/E
pricier
sector median 17.6× · 66th pct
21.4×pricier
EV / EBITDA
pricier
sector median 15.8× · 82nd pct
27.0×pricier
Price / sales
pricier
sector median 3.1× · 86th pct
9.1×pricier
Price / book
pricier
sector median 3.5× · 77th pct
6.5×pricier
FCF yield
cheaper
sector median 4.1% · 64th pct
5.2%cheaper
Forward EPS $1.56 vs trailing $0.85 (+83% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
88.1%
Operating margin
29.6%
FCF margin
46.7%
Net margin
25.5%
Return on equity
18.2%
Return on invested capital
22.3%
Net debt / EBITDA
-1.3×
Current ratio
6.1×
Interest cover
–
Cash conversion (OCF/NI)
1.8×
Piotroski F-score 6/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved
Altman Z-score 23.1 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$31
-7%
Analysts
18
Hold
Range
$18–$47
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2026 | $644.9M | $196.1M | $326.5M |
| 2025 | $570.4M | $223.2M | $273.3M |
| 2024 | $475.4M | $147.6M | $183.9M |
| 2023 | $419.1M | $112.8M | $177.9M |
| 2022 | $343.5M | $154.8M | $124.7M |
| 2021 | $206.9M | $50.2M | $82.7M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +15.5%.
Earnings
Next report: 2026-11-05 · during market · EPS est 0.35
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | 0.30 | 0.29 | -4.2% |
| 2026-05-13 | 0.28 | 0.26 | -7.9% |
| 2026-02-05 | 0.45 | 0.46 | +2.9% |
| 2025-11-06 | 0.38 | 0.45 | +18.7% |
| 2025-08-07 | 0.31 | 0.36 | +17.2% |
| 2025-05-15 | 0.27 | 0.38 | +39.3% |
| 2025-02-06 | 0.34 | 0.45 | +34.0% |
| 2024-11-07 | 0.26 | 0.30 | +17.0% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $156.6M | +7.3% |
| 2026-03-31 | $145.4M | – |
| 2025-12-31 | $185.1M | – |
| 2025-09-30 | $168.5M | – |
| 2025-06-30 | $145.9M | – |
Analyst actions
Evercore ISI Group
PT $35
2026-09-29 · main
In-Line → In-LinePT $35
Freedom Capital Markets
PT $27
2026-09-08 · down
Buy → HoldPT $27
Barclays
PT $27
2026-08-21 · main
Equal-Weight → Equal-WeightPT $27
Truist Securities
PT $24
2026-08-13 · main
Hold → HoldPT $24
Wells Fargo
PT $18
2026-08-10 · down
Equal-Weight → UnderweightPT $18
JP Morgan
PT $31
2026-08-07 · main
Neutral → NeutralPT $31
Insider trades
Sitaram Siddharth
$80.2K
Chief Accounting Officer · 2026-10-14
SELL$80.2K
Wampler Kira Scherer
$57.8K
Director · 2026-10-01
SELL$57.8K
Yang Watkin Phoebe L.
$34.5K
Director · 2026-09-30
SELL$34.5K
Sitaram Siddharth
$54.0K
Chief Accounting Officer · 2026-09-15
SELL$54.0K
Wampler Kira Scherer
$52.7K
Director · 2026-09-01
SELL$52.7K
Wampler Kira Scherer
$49.9K
Director · 2026-08-25
SELL$49.9K
Sitaram Siddharth
$44.1K
Chief Accounting Officer · 2026-08-13
SELL$44.1K
Cabral Timothy S
$293.3K
Director · 2026-08-07
SELL$293.3K
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
Stats refreshed 2026-10-20 18:02:46 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.